Nothing Special   »   [go: up one dir, main page]

IL202318A0 - 5-heteroaryl substituted indazoles as kinase inhibitors - Google Patents

5-heteroaryl substituted indazoles as kinase inhibitors

Info

Publication number
IL202318A0
IL202318A0 IL202318A IL20231809A IL202318A0 IL 202318 A0 IL202318 A0 IL 202318A0 IL 202318 A IL202318 A IL 202318A IL 20231809 A IL20231809 A IL 20231809A IL 202318 A0 IL202318 A0 IL 202318A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
heteroaryl substituted
substituted indazoles
indazoles
heteroaryl
Prior art date
Application number
IL202318A
Original Assignee
Abbott Gmbh & Co Kg
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg, Abbott Lab filed Critical Abbott Gmbh & Co Kg
Publication of IL202318A0 publication Critical patent/IL202318A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
IL202318A 2007-06-08 2009-11-24 5-heteroaryl substituted indazoles as kinase inhibitors IL202318A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93396007P 2007-06-08 2007-06-08
PCT/US2008/065727 WO2008154241A1 (en) 2007-06-08 2008-06-04 5-heteroaryl substituted indazoles as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL202318A0 true IL202318A0 (en) 2010-06-30

Family

ID=39951673

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202318A IL202318A0 (en) 2007-06-08 2009-11-24 5-heteroaryl substituted indazoles as kinase inhibitors

Country Status (13)

Country Link
EP (1) EP2167491A1 (en)
JP (2) JP5451602B2 (en)
KR (1) KR20100032886A (en)
CN (1) CN101790526A (en)
AU (1) AU2008262038A1 (en)
BR (1) BRPI0811065A2 (en)
CA (1) CA2689117A1 (en)
IL (1) IL202318A0 (en)
MX (1) MX2009013213A (en)
RU (1) RU2487873C2 (en)
SG (1) SG182187A1 (en)
WO (1) WO2008154241A1 (en)
ZA (1) ZA200908624B (en)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
AU2007218059A1 (en) 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as ERK inhibitors
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2157859A4 (en) * 2007-06-19 2011-01-12 Takeda Pharmaceutical Indazole compounds for activating glucokinase
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
BRPI0816095A2 (en) * 2007-08-30 2015-03-03 Takeda Pharmaceutical COMPOUND OR SALT OF THE SAME, PRODUCT, PHARMACEUTICAL AGENT, METHODS FOR ANTAGONIZING AN ANDROGEN RECEIVER AND FOR PREVENTING / TREATING CANCER, AND, USE OF THE COMPOUND OR PRODUCT OF THE SAME.
ES2556353T3 (en) 2008-02-21 2016-01-15 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CL2009001158A1 (en) 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compounds derived from carboxylic acids, such as 5,6-dihiro-4h-pyrrolo [3,4-c] pyrazole, furo [3,2-c] pyrazole, thieno [2,3-c] pyrazole, 4,5 , 6,7-tetrahydropyrazole [4,3-c] pyridine and indazole; pharmaceutical composition; and its use in the treatment of cell proliferative disorders associated with altered protein kinase activity, such as cancer.
ES2548141T3 (en) * 2008-11-20 2015-10-14 Glaxosmithkline Llc Chemical compounds
EP2987487B1 (en) 2009-08-10 2020-10-07 Samumed, LLC Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
JP5822844B2 (en) 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー 1H-pyrazolo [3,4-b] pyridine and therapeutic use thereof
UY33213A (en) * 2010-02-18 2011-09-30 Almirall Sa PIRAZOL DERIVATIVES AS JAK INHIBITORS
KR101233082B1 (en) 2010-02-25 2013-02-14 주식회사 이큐스앤자루 A composition containing of novel imidazole pyrazine compound having Influenza virus activity for treating antivirus
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
RU2012136643A (en) * 2010-04-28 2014-06-10 Дайити Санкио Компани, Лимитед [5,6] - HETEROCYCLIC COMPOUND
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2012084704A1 (en) 2010-12-20 2012-06-28 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
JP5918264B2 (en) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Hepatitis C inhibitor and use thereof
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CN102675286B (en) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 One class indazole compounds and preparation method thereof, purposes and pharmaceutical composition
PT2694510E (en) * 2011-04-07 2016-02-08 Bayer Pharma AG Imidazopyridazines as akt kinase inhibitors
MX355852B (en) * 2011-08-12 2018-05-02 Hoffmann La Roche PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE.
CN103929963A (en) 2011-09-14 2014-07-16 萨穆梅德有限公司 Indazole-3-carboxamides and their use as WNT/beta-CATENIN signaling pathway inhibitors
JP6169104B2 (en) 2011-12-27 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Heteroarylpiperidine derivatives and heteroarylpiperazine derivatives as fungicides
MX351287B (en) * 2012-02-21 2017-10-09 Acraf 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors.
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ741907A (en) 2012-05-04 2020-02-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
TW201406758A (en) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd Tricyclic compounds
CN105120862A (en) 2013-01-08 2015-12-02 萨穆梅德有限公司 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9440952B2 (en) 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JO3383B1 (en) * 2013-03-14 2019-03-13 Lilly Co Eli CDC7 Inhibitors
CA2915622C (en) * 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
BR112016018555B1 (en) 2014-02-13 2024-01-23 Incyte Holdings Corporation CYCLOPROPYLAMINES AS LSD1 INHIBITORS, THEIR USE, PHARMACEUTICAL COMPOSITION COMPRISING THEM AND METHOD OF LSD1 INHIBITION
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123465A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
BR112016021626A2 (en) 2014-03-20 2018-05-15 Samumed, Llc 5-substituted indazol-3-carboxamides and their preparation and use
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
JP6675334B2 (en) * 2014-06-25 2020-04-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Imidazo [1,2-a] pyrazin-1-ylbenzamide compounds for treating spinal muscular atrophy
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
JP6543342B2 (en) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． Conjugation of a pharmaceutically active agent with a transthyretin ligand via a regulatable linker to extend serum half life
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
SG11201705821XA (en) * 2015-03-02 2017-08-30 Rigel Pharmaceuticals Inc TGF-ß INHIBITORS
PE20180455A1 (en) 2015-04-03 2018-03-05 Incyte Corp HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
EA035534B1 (en) 2015-08-12 2020-06-30 Инсайт Корпорейшн Salts of an lsd1 inhibitor
EP3370721A4 (en) 2015-11-06 2019-05-22 Samumed, LLC Treatment of osteoarthritis
US20170273307A1 (en) * 2016-03-28 2017-09-28 Trent University Silane-based antimicrobial coatings and methods of making and using the same
JP6999574B2 (en) 2016-04-22 2022-01-18 インサイト・コーポレイション Preparation of LSD1 inhibitor
PT3464285T (en) 2016-06-01 2022-12-20 Biosplice Therapeutics Inc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
ES2890924T3 (en) * 2016-09-21 2022-01-25 Vectus Biosystems Ltd Imidazole derivatives for the treatment of hypertension and/or fibrosis
DK3515894T3 (en) 2016-09-23 2021-07-05 Novartis Ag INDAZOLE COMPOUNDS FOR USE OF T tendon and / or ligament injuries
JOP20190053A1 (en) 2016-09-23 2019-03-21 Novartis Ag Aza-indazole compounds for use in tendon and/or ligament injuries
CN110709082A (en) 2016-10-21 2020-01-17 萨穆梅德有限公司 Methods of use of indazole-3-carboxamides and their use as inhibitors of the Wnt/beta-catenin signaling pathway
MA46696A (en) 2016-11-07 2019-09-11 Samumed Llc READY-TO-USE SINGLE-DOSE INJECTABLE FORMULATIONS
PL3689868T3 (en) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
AU2018222739C1 (en) 2017-02-17 2024-10-03 Eidos Therapeutics, Inc. Processes for preparing AG-10, its intermediates, and salts thereof
WO2019001572A1 (en) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
ES2930804T3 (en) * 2017-06-30 2022-12-22 Beijing Tide Pharmaceutical Co Ltd RHO-associated protein kinase inhibitor, pharmaceutical composition that comprises it, as well as method of preparation and use thereof
CA3088577A1 (en) 2018-02-15 2019-08-22 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
MA52137A (en) 2018-03-23 2021-01-27 Eidos Therapeutics Inc METHODS OF TREATMENT OF TTR AMYLOSIS USING AG10
JP7187575B2 (en) * 2018-04-18 2022-12-12 メッドシャイン ディスカバリー インコーポレイテッド Benzopyrazole compounds as RHO kinase inhibitors
MX2021001761A (en) 2018-08-17 2021-04-19 Eidos Therapeutics Inc Formulations of ag10.
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN111138426B (en) * 2018-11-02 2023-03-10 安徽中科拓苒药物科学研究有限公司 Indazole kinase inhibitor and application thereof
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN110218694A (en) * 2019-05-30 2019-09-10 华中农业大学 A kind of kiwifruit fruit amyloplaste extracting method
TW202120517A (en) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 Process of making cftr modulators
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TW202115092A (en) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 Modulators of cystic fibrosis transmembrane conductance regulator
CN111171023B (en) * 2020-01-10 2021-12-21 中国药科大学 Compound with Pim1 inhibitory activity and preparation method and medical application thereof
CN113350347B (en) * 2020-03-05 2023-07-04 安徽中科拓苒药物科学研究有限公司 Use of indazoles
JP2023540674A (en) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Compounds and compositions for treating conditions associated with STING activity
EP4225750A1 (en) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN112266378B (en) * 2020-11-09 2021-10-12 延边大学 Imidazole derivative containing indazole structure and preparation method and application thereof
CN113336759B (en) * 2020-12-25 2022-12-06 中国药科大学 Bromodomain protein 4 small molecule inhibitor, preparation method and application thereof
CN117529475A (en) * 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 Heterobicyclic compounds containing urea or analogs for the treatment of diseases associated with STING activity and compounds thereof
KR20230056824A (en) * 2021-10-20 2023-04-28 전북대학교산학협력단 PAK4 inhibitors and use thereof
WO2023186773A1 (en) 2022-03-30 2023-10-05 Nerviano Medical Sciences S.R.L. Substituted 3-amino indazole derivatives as kinase inhibitors
CN114651898B (en) * 2022-03-31 2024-04-05 天津溢佳同惠科技集团有限公司 Triazole feed additive for improving immunity as well as preparation method and application thereof
WO2023218201A1 (en) * 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
KR102607237B1 (en) * 2023-06-07 2023-11-30 주식회사 젠센 New triazole substituted indazole derivatives and use thereof
CN116891460A (en) * 2023-07-12 2023-10-17 浙江大学 Indazole derivative or pharmaceutically acceptable salt thereof and application thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU54202A (en) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
ATE339419T1 (en) * 2002-08-02 2006-10-15 Vertex Pharma PYRAZOLE-CONTAINING COMPOSITIONS AND THEIR USE AS GSK-3 INHIBITORS
GB2391557A (en) * 2002-08-06 2004-02-11 Richard Stone Forming fabric for papermaking
FR2845382A1 (en) * 2002-10-02 2004-04-09 Sanofi Synthelabo INDAZOLECARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
RU2339624C2 (en) * 2002-12-12 2008-11-27 Авентис Фарма С.А. Derivatives of aminoindazols and their application as kinases inhibitors
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20080293716A1 (en) * 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds
FR2867778B1 (en) * 2004-03-16 2006-06-09 Sanofi Synthelabo USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF MALARIA
CA2567977A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
DE102004028862A1 (en) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-aminoindazoles
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP1758873A1 (en) * 2004-06-22 2007-03-07 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ZA200704959B (en) * 2004-12-27 2009-04-29 Alcon Inc Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
EP1891051A2 (en) * 2005-04-29 2008-02-27 Celgene Corporation Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
JP5255559B2 (en) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ Indazole compound

Also Published As

Publication number Publication date
BRPI0811065A2 (en) 2014-12-02
EP2167491A1 (en) 2010-03-31
SG182187A1 (en) 2012-07-30
RU2009149696A (en) 2011-07-20
CA2689117A1 (en) 2008-12-18
ZA200908624B (en) 2015-08-26
JP5451602B2 (en) 2014-03-26
KR20100032886A (en) 2010-03-26
JP2014074057A (en) 2014-04-24
MX2009013213A (en) 2010-03-30
CN101790526A (en) 2010-07-28
AU2008262038A1 (en) 2008-12-18
JP2010529137A (en) 2010-08-26
WO2008154241A1 (en) 2008-12-18
RU2487873C2 (en) 2013-07-20

Similar Documents

Publication Publication Date Title
IL202318A0 (en) 5-heteroaryl substituted indazoles as kinase inhibitors
HUS2000049I1 (en) Substituted indazole derivatives active as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
EP2346508A4 (en) Heterocyclic kinase inhibitors
HK1117523A1 (en) Substituted benzimidazoles as kinase inhibitors
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
ZA201104469B (en) Carbazole carboxamide compounds useful as kinase inhibitors
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ME02455B (en) Benzodioxinyl substituted indazoles derivatives
IL199627A0 (en) 5-pyridinone substituted indazoles
HK1142592A1 (en) Alkynylpyrimidines as tie2 kinase inhibitors
IL213464A0 (en) Kinase inhibitor compounds
IL210573A0 (en) Compounds as kinase inhibitors
EP2222166A4 (en) Heterocyclic kinase inhibitors
IL207225A0 (en) Indazole derivatives
IL199628A0 (en) 5-furopyridinone substituted indazoles
EP2231152A4 (en) Thienopyranones as kinase inhibitors
IL205602A0 (en) Pyrazole derivatives as 5-lo inhibitors
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors